William Blair initiated coverage on Corbus Pharma
$CRBP
Biotechnology: Pharmaceutical Preparations
Health Care
William Blair initiated coverage of Corbus Pharma with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2025 | $28.00 | Buy | B. Riley Securities |
| 2/28/2025 | Outperform | William Blair | |
| 12/2/2024 | Overweight | Piper Sandler | |
| 7/30/2024 | $85.00 | Outperform | Wedbush |
| 7/22/2024 | $80.00 | Buy | H.C. Wainwright |
| 6/26/2024 | $85.00 | Buy | B. Riley Securities |
| 6/3/2024 | $60.00 → $80.00 | Outperform | Oppenheimer |
| 5/13/2024 | $77.00 | Outperform | RBC Capital Mkts |
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)
B. Riley Securities resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $28.00
William Blair initiated coverage of Corbus Pharma with a rating of Outperform
Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight
SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)
SCHEDULE 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75 million public offering, extending cash runway into 2028Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025 NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025. "This has been a productive period for Cor
NORWOOD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced it will be participating in the following investor conferences. Guggenheim's Second Annual Healthcare Innovation Conference in BostonFormat: Presentation and one-on-one investor meetings Date: November 12, 2025 Presentation time: 1:00pm ET Webcast link: Click here Jefferies Global Healthcare Conference in LondonFormat: Presentation and one-on-one investor meetingsDate: November 18, 2025Presentation time: 4:00pm GMTWebcast Link: Click here Evercore's 8th Annual Healthcare Conference in MiamiFormat: Presentation
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,025,000 shares of its common stock, at a public offering price of $12.9999 per pre-funded warrant, for a total public offering size of approximately $75 million, before deducting underwriting discounts and estimated offering expenses. The exercise price of the pre-funded warrants is $0.0001 per sh
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h